Background: BV is an anti-CD30 antibody-drug conjugate indicated for the treatment of CD30+ rrHL following ASCT or following at least two prior therapies in patients who are ASCT-ineligible. Clinical outcomes in the ASCT-ineligible population have not yet been evaluated in a real-world study. We aimed to describe outcomes in real-world ASCT-ineligible patients with rrHL in two countries known to have different practice patterns in rrHL. Methods: This was a retrospective medical chart review study that enrolled patients at 45 clinical sites representative of routine practice in Germany and the UK. The study included patients ≥18 years old at the time of HL diagnosis, who progressed after multi-drug chemotherapy regimens between 1 January 2008 and 30 June 2014 and were not ASCT candidates as identified by their clinicians, were subsequently treated with BV, and were not enrolled in an HL-related clinical trial. Patient demographics, clinical characteristics, and treatment characteristics were described. Clinical outcomes included best response to treatment, progression-free survival (PFS), overall survival (OS), and adverse events (AEs). All outcomes were descriptive, and reported in the full study population and by country. Results: A total of 136 patients were included in this analysis (78 in Germany and 58 in the UK). The median age of study patients at HL diagnosis was 70 years, and 58% were male. Nearly all patients had classical HL (96%), and over half had non-bulky (<5 cm) disease (55%). The most common reasons for ASCT ineligibility were comorbidities (74%), age (57%), and disease progression (12%). Coronary artery disease (39%), diabetes (38%), and chronic pulmonary disease (24%) were the most common comorbidities among study patients. Eighty-five percent of patients received at least 2 lines of treatment prior to initiating BV. At the time of BV initiation, 24% of patients had stage IV disease and 21% had extranodal involvement. The median duration of follow-up was 3.2 years from the time of HL diagnosis. Three fourths of patients had a partial or complete response (Table). Other events of interest included leukopenia (13%; of which 53% were serious), neuropathy (10%; 8% serious), and anemia (9%; 42% serious). Conclusion: Progression-free and overall survival in ASCT-ineligible patients receiving BV were 15.1 and 17.8 months, respectively, after initiation of therapy.